Thomas Wildhaber Senior Analyst Group Finance

Since 2016 Thomas Wildhaber has been working as an Analyst for Swiss Re. During his internal rotation in 2017, he investigated the new CRISPR technology. From 2012 to 2016 Thomas Wildhaber worked for a consulting company, where he was involved in projects for biotech companies.

Thomas Wildhaber holds a PhD in molecular biology from the ETH Zurich.